The first anti-LAG3 human monoclonal antibody, Relatlimab (Bristol-Myers Squibb), has been recently approved (March 2022) by FDA in combination with Nivolumab for metastatic melanoma therapy (8) and is currently under study in 46 randomized clinical trials in oncology. This evidence concerns the gene LAG3 and metastatic melanoma.